Mary Kay Fenton's Net Worth

$3.23 Million

Estimate Recalculated May 16, 2024 04:42PM EST

Who is Mary Kay Fenton?

Mary Kay Fenton has an estimated net worth of $3.23 Million. This is based on reported shares across multiple companies, which include Talaris Therapeutics, Inc., Oncorus, Inc., and ACHILLION PHARMACEUTICALS INC.

SEC CIK

Mary Kay Fenton's CIK is 0001378589

Past Insider Trading and Trends

2022 was Mary Kay Fenton's most active year for acquiring shares with 3 total transactions. Mary Kay Fenton's most active month to acquire stocks was the month of November. 2011 was Mary Kay Fenton's most active year for disposing of shares, totalling 4 transactions. Mary Kay Fenton's most active month to dispose stocks was the month of December. 2015 saw Mary Kay Fenton paying a total of $98,175.00 for 56,625 shares, this is the most they've acquired in one year. In 2015 Mary Kay Fenton cashed out on 113,250 shares for a total of $648,480.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Talaris Therapeutics, Inc. (TRML) Snapshot price: $35.4125

Chief Financial Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-15.98%
-12.95K
$3.08
-$39,873.68
68.05K
Jul 3
Form 4
—
0
—
—
0
Feb 1
Form 4
+8,000.00%
80K
—
—
81K
Sep 10
Form 4
∞
1K
$13.00
$13,000.00
1K
Dec 31 - Feb 1
Form 3
—
0
—
—
0
No matching records found

Oncorus, Inc. (ONCR) Snapshot price: $0.024

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Jun 23
Form 4
—
0
—
—
0
Jun 16
Form 3
—
0
—
—
0
No matching records found

ACHILLION PHARMACEUTICALS INC No price found

Chief Financial Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Feb 9
Form 4
—
0
—
—
0
Jan 17
Form 4
∞
2.5K
$4.11
$10,275.00
2.5K
Dec 5
Form 4
—
0
—
—
0
Jan 20
Form 4
—
0
$5.57
-$392,805.00
0
Dec 28
Form 4
—
0
$10.00
-$157,500.00
0
Jan 23
Form 4
—
0
—
—
0
Dec 2
Form 4
—
0
—
—
0
Mar 4
Form 4
—
0
—
—
0
Dec 17
Form 4
—
0
—
—
0
Dec 18
Form 4
-100.00%
-4.38K
$6.41
-$151,362.50
0
Jan 9 - Jan 10
Form 4
—
0
—
—
0
Dec 12
Form 4
-49.28%
-4.25K
$7.50
-$31,875.00
4.38K
Apr 5 - Apr 6
Form 4
-31.68%
-4.00K
$7.50
-$30,000.00
8.63K
Mar 30
Form 4
-40.94%
-8.75K
$5.00
-$43,750.00
12.63K
Jan 13
Form 4
—
0
—
—
0
Dec 16
Form 4
—
0
—
—
0
Dec 18
Form 4
—
0
—
—
0
Dec 15
Form 4
+17.12%
3.13K
$1.60
$5,000.00
21.38K
Sep 5
Form 4
—
0
—
—
0
Dec 14
Form 4
∞
1.25K
$1.60
$2,000.00
1.25K
Dec 18
Form 4
—
0
—
—
0
Dec 19
Form 3
—
0
—
—
0
No matching records found

Cullinan Therapeutics, Inc. (CGEM) No price found

Chief Financial Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
—
—
0
Apr 29
Form 3
—
0
—
—
0
No matching records found